Oliver Simic
Novartis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Oliver Simic.
Immunology and Cell Biology | 2018
Maureen Bardet; Adeline Unterreiner; Claire Malinverni; Frédérique Lafossas; Corinne Vedrine; Danielle Boesch; Yeter Kolb; Daniel Kaiser; Anton Glück; Martin A. Schneider; Andreas Katopodis; Martin Renatus; Oliver Simic; Achim Schlapbach; Jean Quancard; Catherine H. Regnier; Guido Bold; Carole Pissot-Soldermann; José M. Carballido; Jiri Kovarik; Thomas Calzascia; Frédéric Bornancin
Mucosa‐associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is essential for immune responses triggered by antigen receptors but the contribution of its paracaspase activity is not fully understood. Here, we studied how MALT1 proteolytic function regulates T‐cell activation and fate after engagement of the T‐cell receptor pathway. We show that MLT‐827, a potent and selective MALT1 paracaspase inhibitor, does not prevent the initial phase of T‐cell activation, in contrast to the pan‐protein kinase C inhibitor AEB071. However, MLT‐827 strongly impacted cell expansion after activation. We demonstrate this is the consequence of profound inhibition of IL‐2 production as well as reduced expression of the IL‐2 receptor alpha subunit (CD25), resulting from defective canonical NF‐κB activation and accelerated mRNA turnover mechanisms. Accordingly, MLT‐827 revealed a unique transcriptional fingerprint of MALT1 protease activity, providing evidence for broad control of T‐cell signaling pathways. Altogether, this first report with a potent and selective inhibitor elucidates how MALT1 paracaspase activity integrates several T‐cell activation pathways and indirectly controls gamma‐chain receptor dependent survival, to impact on T‐cell expansion.
Chemical Communications | 2003
Carsten Bolm; Marinella Verrucci; Oliver Simic; Pier Giorgio Cozzi; Gerhard Raabe; Hiroaki Okamura
Quinoline-based C1-symmetric sulfoximines have been used as chiral ligands in copper-catalyzed asymmetric hetero Diels-Alder reactions leading to cycloadducts with up to 96% ee.
PLOS ONE | 2013
Abhiruchi Agarwal; Andreas Boettcher; Rainer Kneuer; Farid Sari-Sarraf; Adriana Donovan; Julian Woelcke; Oliver Simic; Trixi Brandl; Thomas Krucker
Background and Aims Endoprotease activation is a key step in acute pancreatitis and early inhibition of these enzymes may protect from organ damage. In vivo models commonly used to evaluate protease inhibitors require animal sacrifice and therefore limit the assessment of dynamic processes. Here, we established a non-invasive fluorescence imaging-based biomarker assay to assess real-time protease inhibition and disease progression in a preclinical model of experimental pancreatitis. Methods Edema development and trypsin activation were imaged in a rat caerulein-injection pancreatitis model. A fluorescent “smart” probe, selectively activated by trypsin, was synthesized by labeling with Cy5.5 of a pegylated poly-L-lysine copolymer. Following injection of the probe, trypsin activation was monitored in the presence or absence of inhibitors by in vivo and ex vivo imaging. Results We established the trypsin-selectivity of the fluorescent probe in vitro using a panel of endopeptidases and specific inhibitor. In vivo, the probe accumulated in the liver and a region attributed to the pancreas by necropsy. A dose dependent decrease of total pancreatic fluorescence signal occurred upon administration of known trypsin inhibitors. The fluorescence-based method was a better predictor of trypsin inhibition than pancreatic to body weight ratio. Conclusions We established a fluorescence imaging assay to access trypsin inhibition in real-time in vivo. This method is more sensitive and dynamic than classic tissue sample readouts and could be applied to preclinically optimize trypsin inhibitors towards intrapancreatic target inhibition.
Bioorganic & Medicinal Chemistry Letters | 2018
Achim Schlapbach; Laszlo Revesz; Carole Pissot Soldermann; Thomas Zoller; Catherine H. Regnier; Frédéric Bornancin; Thomas Radimerski; Jutta Blank; Ansgar Schuffenhauer; Martin Renatus; P. Erbel; Samu Melkko; Richard Heng; Oliver Simic; Ralf Endres; Markus Wartmann; Jean Quancard
Starting from a weak screening hit, potent and selective inhibitors of the MALT1 protease function were elaborated. Advanced compounds displayed high potency in biochemical and cellular assays. Compounds showed activity in a mechanistic Jurkat T cell activation assay as well as in the B-cell lymphoma line OCI-Ly3, which suggests potential use of MALT1 inhibitors in the treatment of autoimmune diseases as well as B-cell lymphomas with a dysregulated NF-κB pathway. Initially, rat pharmacokinetic properties of this compound series were dominated by very high clearance which could be linked to amide cleavage. Using a rat hepatocyte assay a good in vitro-in vivo correlation could be established which led to the identification of compounds with improved PK properties.
Archive | 2010
Trixi Brandl; Prakash Raman; Pascal Rigollier; Mohindra Seepersaud; Oliver Simic
Journal of Molecular Biology | 2006
Nils Ostermann; Jörg Eder; Ulf Eidhoff; Florence Zink; Ulrich Hassiepen; Susanne Worpenberg; Jürgen Maibaum; Oliver Simic; Ulrich Hommel; Bernd Gerhartz
Archive | 2013
Eva Altmann; Ulrich Hommel; Edwige Liliane Jeanne Lorthiois; Juergen Klaus Maibaum; Nils Ostermann; Jean Quancard; Stefan Andreas Randl; Olivier Rogel; Oliver Simic; Anna Vulpetti
Organic Letters | 2003
Carsten Bolm; Marc Martin; Oliver Simic; Marinella Verrucci
Synthesis | 2002
Carsten Bolm; Christian P. R. Hackenberger; Oliver Simic; Marinella Verrucci; Dirk Müller; Frank Bienewald
Synlett | 2001
Carsten Bolm; Oliver Simic; Marc Martin